logo for Antengene

Antengene

Business Services · China · 329 Employees

View Company Info for Free

About

Headquarters

Soho Plaza 1065 W Zhongshan Road Suites 1206-12...

Phone Number

+86 1050951066

Revenue

<$5 Million

Industry

Drug Manufacturing & Research Pharmaceuticals Healthcare

Who is Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 23 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) in China, South Korea, Singapore and Australia approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.Read more

Antengene's Social MediaPopular SearchesAntengene CorpAntengeneAntengene Corporation LtdAntengene CoAntengene Biotech LLCSIC Code 28,283NAICS Code 54,541Show more

Antengene Org Chart

Jianming Mei

Founder, Chairman & Chief Executive Officer

PhoneEmail
Yiteng Liu

Chief Operating Officer

PhoneEmail

PhoneEmail

PhoneEmail

Similar Companies to Antengene

  1. 323
    $63.4M

    1

  2. 99
    $54.5M

    2

  3. 269
    $52.6M

    3

  4. 3,000
    $634M

    4

  5. 93
    <$5M

    5

  6. 35
    <$5M

    6

See more similar companies

Antengene Tech Stack

A closer look at the technologies used by Antengene

Antengene News & Media

  • Antengene To Present One Oral and Four Abstracts at ASCO 2024

    Oral Presentation:a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor (XPO1 Inhibitor) Journal Publication: the first-in-human Phase I dose-escalation study of ATG-017 (ERK1/2 inhibitor) in patients with advanced solid tumors SHANGHAI and HONG KONG, May 24, 2024 /PRNewswire/ -- Antengene
  • Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

    Oral session:ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer Three Poster presentations: Phase I/II studies for ATG-031 (anti-CD24 monoclonal antibody) and ATG-022 (Claudin 18.2 antibody-drug conjugate) and selinexor (XPO1 Inhibitor) SHANGHAI and HONG KONG, April 25, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, deve
  • Antengene Presents Four Preclinical Posters at AACR 2024

    SHANGHAI and HONG KONG, April 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Dieg
  • Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

    Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets RMB1.188 billion cash expected to support planned operations SHANGHAI and HONG KONG, March 22, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biop
Read more news

Frequently Asked Questions regarding Antengene

Where is Antengene located?
Antengene's headquarters are located at Soho Plaza 1065 W Zhongshan Road Suites 1206-1209 Block B Zhongshan, Changning, Shanghai, China
What is Antengene's phone number?
Antengene's phone number is +86 1050951066
What is Antengene's official website?
Antengene's official website is www.antengene.com
What is Antengene's Revenue?
Antengene's revenue is <$5 Million
What is Antengene's SIC code?
Antengene's SIC: 28,283
What is Antengene's NAICS code?
Antengene's NAICS: 54,541
How many employees does Antengene have?
Antengene has 329 employees
What industry does Antengene belong to?
Antengene is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, Healthcare
What is Antengene competition?
Antengene top competitors include: George Clinical, Theravance Biopharma, Neuren Pharmaceuticals, Novotech
What technology does Antengene use?
Some of the popular technologies that Antengene uses are: ASP.NET, PHP, jQuery Migrate, nginx
Who is the CEO of Antengene?
Antengene's CEO is Jianming Mei
How do I contact Antengene?
Antengene contact info: Phone number: +86 1050951066 Website: www.antengene.com
What does Antengene do?

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most a... dvanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 23 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) in China, South Korea, Singapore and Australia approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.Read More

What are Antengene social media links?
Antengene Linkedin page
Is Antengene a public company?
Antengene is private company therefore does not currently have an official ticker symbol
See more information about Antengene

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.